Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
4.44
-0.03 (-0.67%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.40 - 4.50
52 week 3.26 - 6.28
Open 4.50
Vol / Avg. 1.35M/2.40M
Mkt cap 1.07B
P/E     -
Div/yield     -
EPS -0.26
Shares 242.04M
Beta -0.85
Inst. own 59%
Jul 30, 2015
Q2 2015 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 12, 2015
Arena Pharmaceuticals Inc Annual Shareholders Meeting
Jun 12, 2015
Arena Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 1, 2015
Arena Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 13, 2015
Arena Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Arena Pharmaceuticals Inc Earnings call - Webcast
May 11, 2015
Q1 2015 Arena Pharmaceuticals Inc Earnings Release
Apr 15, 2015
Arena Pharmaceuticals Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -198.23% -163.67%
Operating margin -177.42% -284.75%
EBITD margin - -259.97%
Return on average assets -30.52% -19.64%
Return on average equity -110.56% -86.94%
Employees 325 -
CDP Score - -

Address

6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company's drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserin's once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Company's other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Officers and directors

Jack Lief Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert E. Hoffman Chief Financial Officer, Senior Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dominic P. Behan Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Craig M. Audet Ph.D. Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
William R. Shanahan Jr., M.D., J.D. Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 76
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 68
Bio & Compensation  - Reuters
Harry F. Hixson Jr., Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters